Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TOLVAPTAN
- Efficacy and Safety Evaluation of Tolvaptan in the Treatment of Patients With RHF Caused by PAH
- Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
- HYDROchlorothiazide to PROTECT Polycystic Kidney Disease Patients and Improve Their Quality of Life
- Open-label, Roll-over Study to Assess Safety of Lixivaptan in Participants With ADPKD Who Completed Study PA-ADPKD-303
- PB to Treat Hereditary Nephrogenic Diabetes Insipidus, ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
- To Study Effect of the Combination of Midodrine and Tolvaptan Versus Tolvaptan Alone in Patients With Severe Hyponatremia in Cirrhosis(TOLMINA Trial)
- Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
- A Study to See if Tolvaptan Can Delay Dialysis in Infants and Children Who at Enrollment Are 28 Days to Less Than 12 Weeks Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)
- Tolvaptan add-on Therapy to Overcome Loop Diuretic Resistance in Acute Heart Failure With Renal Dysfunction
- Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
- Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease
- Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST)
- Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD
- Efficacy and Safety Trial of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
- Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease
- Lixivaptan in a Single Subject With Intractable Pain Due to Polycystic Kidney Disease
- Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease
- Tolvaptan-Octreotide LAR Combination in ADPKD
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics Study of Tolvaptan in Pediatric Congestive Heart Failure (CHF) Patients With Volume Overload
- Clinical Pharmacology Trial to Investigate the Dose of OPC-61815 Injection Equivalent to Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
- A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
- Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)
- Tolvaptan for Advanced or Refractory Heart Failure
- Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
- Efficacy of Tolvaptan on ADPKD Patients
- Regional Tolvaptan Registry
- AiDing Diuresis wIth Tolvaptan (ADD-IT)
- The Safety and Efficacy of Tolvaptan for Patients With Tricuspid Regurgitation and Right Heart Failure After Left Heart Valves Replacement
- Comparison of Oral or Intravenous Thiazides vs Tolvaptan in Diuretic Resistant Decompensated Heart Failure
- Tolvaptan for Patients With Acute Neurological Injuries
- TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
- Effect of the Aquaretic Tolvaptan on Nitric Oxide System
- Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders
- International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia
- A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia
- Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure
- A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
- Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
- Pharmacokinetics and Clinical Response of Tolvaptan in Neurocritical Care Patients
- Aquaresis Utility for Hyponatremic Acute Heart Failure Study
- Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites
- Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease
- Use of Tolvaptan to Reduce Urinary Supersaturation: a Pilot Proof of Principle Study
- V2 Receptor Effects on Fluid Regulation and Performance
- Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)
- An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia
- Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
- A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
- Effects of Tolvaptan in Healthy Adults
- Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
- Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure
- Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia
- Acute Heart Failure Patients With High Copeptin Treated With Tolvaptan Targets Increased AVP Activation for Treatment (ACTIVATE)
- Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites
- The Use of Tolvaptan to Prevent Renal Dysfunction in High Risk Patients With Heart Failure-Pilot Study
- Efficacy and Safety Study of Tolvaptan to Treat Patients With Cardiac Edema
- Targeting Acute Congestion With Tolvaptan in Congestive Heart Failure
- Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)
- Efficacy and Safety of Tolvaptan in the Treatment of Cardiac-Induced Edema in Patients With Heart Failure
- Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management
- Effect of Tolvaptan on Cognitive Function in Cirrhosis
- Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites
- Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
- 8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Effect of Tolvaptan on Mid- to Long-term Prognosis of Heart Failure Patients
- Fractional Urate Excretion in Nonedematous Hyponatremia
- Tolvaptan for In-hospital Hyponatremia
- Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency
- Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
- Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites
- Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites
- Pilot Study of Using Copeptin to Predict Response to Tolvaptan
- Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Tolvaptan for Ascites in Cirrhotic Patients
- A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]
- Bioavailability Study Comparing Tolvaptan Administered Via Nasogastric Tube to Tolvaptan Tablets Swallowed Intact
- Post-Authorisation Safety Study of Samsca (Tolvaptan) Used in Routine Medical Practice
- Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
- Tolvaptan Extension Study in Participants With ADPKD
- Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD
- Tolvaptan in Hyponatremic Cancer Patients
- Pharmacokinetics/Pharmacodynamics (PK/PD) Characteristics of Tolvaptan Tablet in Korean Healthy Male
- A Phase 2 Efficacy and Safety Study of the Tolvaptan Tablets in Patients With Non-hypovolemic Non-acute Hyponatremia
- Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
- Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- "SALT-2 Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
- Heart Pressure Assessment Study With Tolvaptan to Treat Congestive Heart Failure
- "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia
- EVEREST: Efficacy of Vasopressin Antagonism in hEart failuRE: Outcome Study With Tolvaptan
- Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
- Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy Study on the Effects of Tolvaptan on Left Ventricular Dilatation in Congestive Heart Failure Patients
Clinical trials list
click for details